Esperion Therapeutics Inc (NASDAQ:ESPR) — Market Cap & Net Worth
Market Cap & Net Worth: Esperion Therapeutics Inc (ESPR)
Esperion Therapeutics Inc (NASDAQ:ESPR) has a market capitalization of $726.75 Million ($726.75 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #10397 globally and #2772 in its home market, demonstrating a 0.63% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Esperion Therapeutics Inc's stock price $3.18 by its total outstanding shares 239063437 (239.06 Million). Also see total assets of Esperion Therapeutics Inc for a full breakdown of the balance sheet.
Esperion Therapeutics Inc Market Cap History: 2015 to 2026
Esperion Therapeutics Inc's market capitalization history from 2015 to 2026. Data shows change from $5.32 Billion to $760.22 Million (-17.00% CAGR). Also see ESPR cash generation efficiency for how efficiently the company converts equity into cash flow.
Index Memberships
Esperion Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.03% | #294 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #1078 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.04% | #171 of 263 |
Weight: Esperion Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Esperion Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Esperion Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Esperion Therapeutics Inc (ESPR) share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1.58x
Esperion Therapeutics Inc's market cap is 1.58 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $11.00 Billion | $184.47 Million | -$201.81 Million | 59.61x | N/A |
| 2019 | $14.26 Billion | $148.36 Million | -$97.17 Million | 96.08x | N/A |
| 2020 | $6.22 Billion | $227.55 Million | -$143.55 Million | 27.32x | N/A |
| 2021 | $1.20 Billion | $78.45 Million | -$269.11 Million | 15.24x | N/A |
| 2022 | $1.49 Billion | $75.47 Million | -$233.66 Million | 19.73x | N/A |
| 2023 | $714.80 Million | $116.33 Million | -$209.25 Million | 6.14x | N/A |
| 2024 | $525.94 Million | $332.31 Million | -$51.74 Million | 1.58x | N/A |
Competitor Companies of ESPR by Market Capitalization
Companies near Esperion Therapeutics Inc in the global market cap rankings as of September 18, 2026. Review ESPR intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Esperion Therapeutics Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #519 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #633 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #640 globally with a market cap of $43.16 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.62 Billion USD ( CN¥277.61 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #519 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #633 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #640 | GALDERMA GROUP AG | NYSE:GALDY | $43.16 Billion | $37.02 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.62 Billion | CN¥43.52 |
Esperion Therapeutics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Esperion Therapeutics Inc's market cap moved from $5.32 Billion to $ 760.22 Million, with a yearly change of -17.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $760.22 Million | -14.05% |
| 2025 | $884.53 Million | +68.18% |
| 2024 | $525.94 Million | -26.42% |
| 2023 | $714.80 Million | -52.01% |
| 2022 | $1.49 Billion | +24.60% |
| 2021 | $1.20 Billion | -80.77% |
| 2020 | $6.22 Billion | -56.40% |
| 2019 | $14.26 Billion | +29.63% |
| 2018 | $11.00 Billion | -30.13% |
| 2017 | $15.74 Billion | +425.88% |
| 2016 | $2.99 Billion | -43.76% |
| 2015 | $5.32 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Esperion Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $726.75 Million USD |
| MoneyControl | $726.75 Million USD |
| MarketWatch | $726.75 Million USD |
| marketcap.company | $726.75 Million USD |
| Reuters | $726.75 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Esperion Therapeutics Inc
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary h… Read more